98%
921
2 minutes
20
Metabolic and bariatric surgery (MBS) is widely considered the most effective option for treating obesity, a chronic, relapsing, and progressive disease. Recently, the American Society of Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) issued new guidelines on the indications for MBS, which have superseded the previous 1991 National Institutes of Health guidelines. The aim of this study is to establish the first set of consensus guidelines for selecting procedures in Class I and II obesity, using an Expert Modified Delphi Method. In this study, 78 experienced bariatric surgeons from 32 countries participated in a two-round Modified Delphi consensus voting process. The threshold for consensus was set at an agreement or disagreement of ≥ 70.0% among the experts. The experts reached a consensus on 54 statements. The committee of experts reached a consensus that MBS is a cost-effective treatment option for Class II obesity and for patients with Class I obesity who have not achieved significant weight loss through non-surgical methods. MBS was also considered suitable for patients with Type 2 diabetes mellitus (T2DM) and a body mass index (BMI) of 30 kg/m or higher. The committee identified intra-gastric balloon (IGB) as a treatment option for patients with class I obesity and endoscopic sleeve gastroplasty (ESG) as an option for patients with class I and II obesity, as well as for patients with T2DM and a BMI of ≥ 30 kg/m. Sleeve gastrectomy (1) and Roux-en-Y gastric bypass (RYGB) were also recognized as viable treatment options for these patient groups. The committee also agreed that one anastomosis gastric bypass (OAGB) is a suitable option for patients with Class II obesity and T2DM, regardless of the presence or severity of obesity-related medical problems. The recommendations for selecting procedures in Class I and II obesity, developed through an Expert Modified Delphi Consensus, suggest that the use of standard primary bariatric endoscopic (IGB, ESG) and surgical procedures (SG, RYGB, OAGB) are acceptable in these patient groups, as consensus was reached regarding these procedures. However, randomized controlled trials are still needed in Class I and II Obesity to identify the best treatment approach for these patients in the future.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10858961 | PMC |
http://dx.doi.org/10.1038/s41598-024-54141-6 | DOI Listing |
Rheumatol Int
September 2025
Department of Physical Medicine and Rehabilitaton, Ankara Bilkent City Hospital, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Türkiye, Turkey.
The Impact of Obesity and Overweight on Rheumatoid Arthritis Patients: Real-World Insights from a Biologic and Targeted Synthetic DMARDs Registry. The management of rheumatoid arthritis (RA) has advanced with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). However, obesity, a common comorbidity, impacts treatment and disease progression efficacy.
View Article and Find Full Text PDFJ Metab Bariatr Surg
August 2025
Office of Medical Education, Seoul National University College of Medicine, Seoul, Korea.
Obesity represents a major global health challenge, requiring interventions that are both effective and economically sustainable. This review examines the cost-effectiveness of commonly discussed treatment options: glucagon-like peptide-1 receptor agonists (GLP-1 RAs), endoscopic sleeve gastroplasty (ESG), and metabolic/bariatric surgery (MBS). We synthesized evidence from published clinical studies and economic analyses, comparing incremental cost-effectiveness ratios (ICERs) and cost per quality-adjusted life year across obesity severity classes, with particular consideration of implications for Korea's healthcare context.
View Article and Find Full Text PDFEnviron Res
September 2025
Medical Support Center for the Japan Environment and Children's Study, National Research Institute for Child Health and Development, Tokyo, 157-8535, Japan.
This study explored the association between maternal blood lead, cadmium, mercury, and manganese concentrations during pregnancy and body mass index z-scores (zBMI), overweight, and obesity among children aged 0-4 years based on data from the Japan Environment and Children's Study (JECS). After data selection, 93,782 mother-child pairs were selected for analysis. Associations between prenatal metal exposure and obesity in children were explored using the generalized estimating equation (GEE), latent class growth analysis (LCGA), and quantile g-computation models.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFBiophys J
September 2025
CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201 002, India. Electronic address:
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that plays an important role in metabolic regulation, and consequently is a target for type 2 diabetes and obesity therapeutics. Although cholesterol has been reported to be implicated in receptor activation, its interactions with the receptor during the activation cycle have not been probed. Using coarse-grained molecular dynamics simulations, we have characterized the cholesterol interactions with GLP-1R in four conformational states: the inactive, partially active, GLP-1-bound active, and exenatide-bound active conformational states.
View Article and Find Full Text PDF